Morgan Stanley raises Camtek stock price target on HBM growth outlook

Morgan Stanley raised its price target on Camtek to $161 from $151 and boosted 2026 revenue to $574M (from $559M) and EPS to $3.70 (from $3.59); the stock trades at $180.19 (market cap $8.42B), already above the new target. Camtek reported 4Q25 revenue of $128.1M with AI-related HBM and chiplet sales contributing ~50% of sales, but Q1 revenue guidance missed expectations even as the company still forecasts double-digit growth in 2026. MS expects HBM growth of +31% y/y in 2026 (slowing to +23% in 2027) and projects non-China WFE to outgrow China WFE; valuation appears rich with a P/E of 169 and InvestingPro flagging the stock as overvalued. Other analyst moves: Stifel raised its PT to $185 (Buy), Needham to $175 (Buy), while Northland raised its PT to $150 but downgraded to Market Perform.

Analysis

Camtek’s narrative is increasingly a concentrated-growth bet: high exposure to HBM/chiplet inspection and China end-markets makes its earnings highly binary to a handful of OEM cycles. That concentration amplifies competitor dynamics — a smaller player with a premium multiple is more vulnerable to share-pressure from a dominant rival that can bundle tools, offer service scale, and undercut ASPs to protect installed-base economics.

Second-order supply-chain effects favor large, diversified suppliers: if non-China WFE accelerates while China lags, OEM ordering patterns will shift toward vendors with global install footprints and local service networks, shortening windows for smaller vendors to commercialize new products. Conversely, any near-term Chinese demand hiccup creates inventory digestion and lengthened qualification cycles that disproportionately delay revenue recognition for niche inspection vendors.

Key risk windows are near-term guidance prints and the upcoming cadence of WFE data from China and major hyperscaler customers — both can re-price expectations quickly. Over the next 3–12 months, the likely triggers for re-rating are (1) sequential deceleration in win rates vs. the large competitor, (2) evidence of ASP erosion in premium inspection segments, or (3) clearer China capex divergence vs. global WFE growth.

From a portfolio construction angle, this is not a macro call but a dispersion trade: latent volatility around share-shift and guidance clarity creates asymmetric payoff opportunities. Position sizing should assume binary outcomes from competitive wins/losses and the potential for a fast multiple compression if market leadership signals shift within two quarters.

Key Decisions for Investors

• Pair trade (3–9 months): Short CAMT equity versus long KLAC to neutralize broader WFE cyclicality. R/R: target ~2:1 — expect larger downside on CAMT if share-loss evidence emerges; stop-loss if the pair diverges by >15% versus entry.
• Option hedge (earnings/event play, 1–3 months): Buy CAMT put spreads (defined-risk) ahead of next quarterly guidance to capture skew and guidance-driven repricing. Risk limited to premium; reward from >10% guidance miss or guidance-led multiple compression.
• Directional long (6–18 months): Accumulate KLAC on weakness to play consolidation and scale advantages in inspection equipment as non-China WFE accelerates. R/R: asymmetric — limited downside vs. steady cash generation and market-share tailwinds.
• Analyst-chase fade (weeks): If consensus upgrades follow an earnings print without fundamental guidance improvement, trim/short into the pop — historical pattern shows premium names re-rate quickly when follow-through growth is absent. Size as a catalyst play (small allocation, tight risk controls).